Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations

Diabetologia

Volumn 42, Issue 1, 1999, Pages 45-50

  Greig, N H ^a   Holloway, H W ^a   De Ore, K A ^b   Jani, D ^c   Wang, Y ^c   Zhou, J ^c   Garant, M J ^c   Egan, J M ^a,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Db db mice; Exendin 4; GLP 1; Glucose; Wistar rats

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; GLUCOSE BLOOD LEVEL; INSULIN LIKE ACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CARRIER PROTEINS; CROSSES, GENETIC; CYCLIC AMP; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; ENERGY INTAKE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; INSULIN; ISLETS OF LANGERHANS; LIZARDS; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN PRECURSORS; RATS; RATS, WISTAR; RECEPTORS, CELL SURFACE; VENOMS;

EID: 0032932825     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051111     Document Type: Article

References (19)

1. 1. Ghazzi MN, Perez JE, Antonucci TK et al. (1997) Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 46: 433-439
2. 2. UK Prospective Study Group (1995) UK Prospective Diabetes Study 16: Overview of 6 years' therapy of Type II diabetes: a progressive disease. Diabetes 44: 1249-1258
3. 3. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316-1322
4. 4. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36) amide in Type II (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744
5. 5. Elahi D, McAloon-Dyke M, Fukagawa NK et al. (1994) The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51: 63-74
6. 6. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glocose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1-(7-36) amide in Type II (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332
7. 7. Nathan D, Scheiber E, Fogel H, Mosjov S, Habener JF (1992) Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and non-diabetic subjects. Diabetes Care 15: 270-276
8. 8. De Ore K, Greig NH, Halloway HW, Wang Y, Perfetti R, Egan JM (1997) The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test. J Gerontol B Psychol Sci Soc Sci 52:B245-B249
9. 9. Ritzel R, Orskov C, Holst JJ, Nauck MA (1995) Pharmaco-kinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38: 720-725
10. 10. Chen YE, Drucker DJ (1997) Tissus-specific expression of unique mRNAs that encode pro-glucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 272: 4108-4115
11. 11. Goke R, Fehmann H-C, Linn T et al. (1993) Exendin-4 is a potent agonist and truncated exendin-(9-39)-amide an antagonist at the GLP-1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268: 19650-19655
12. 12. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widman C (1993) Cloning and functional expression of the GLP-1 receptor: Demonstration that exendin-4 is an agonist and exendin-3 (9-39) is an antagonist of the receptor. Diabetes 42: 1678-1672
13. 13. Wang Y, Perfetti R, Greig NH et al. (1997) Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 99: 2883-2889
14. 14. Perfetti R, Montrose-Rafizadeh C, Liotta AS, Egan JM (1995) Age-dependent reduction in insulin secretion and insulin mRNA in isolated islets from rats. Am J Physiol 269:E983-E990
15. 15. Montrose-Rafizadeh C, Wang Y, Janczewski AM, Henderson TE, Egan JM (1997) Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness. Mol Cell Endocrinol 130: 109-117
16. 16. Kolligs F, Fehmann H-C, Goke R, Goke B (1995) Reduction of the the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44: 16-19
17. 17. Bhavsar S, Lachappell R, Watkins J, Young A (1998) Comparison of glucose lowering effects of exendin-4 and GLP-1 in diabetic db/db mice. Diabetes 47 [Suppl 1]:A192 (Abstract)
18. 18. Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520
19. 19. Thiele TE, Van Dijk G, Campfield A (1997) Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol 272:R725-R730